You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.
The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.
The company plans to use to the funds to accelerate the commercialization of its CRISPRclean technology and expand into additional markets.
In PNAS this week: droplet-based mRNA sequencing strategy, secretome mouse model, and more.
In a new study, researchers used base editing to extend the lives of mice with a premature aging syndrome.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
Basel, Switzerland-based Lonza will be able to use Arbor's proprietary CRISPR technology in its bioproduction products and services.
The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.